Wishbone
ActiveSummary
The annual accounts of Wishbone for fiscal year 2025 show a net loss of 137% of the equity at the start of that year. The 2025 annual accounts show equity of €1.77M and a net result of €-1.22M. Equity remains stable across the filed fiscal years (±0.9% per year). Its solvency ranks better than 53% of 213 sector peers (fiscal year 2025). The company has been active since 2013 and the Belgian State Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Score 2025
58
/ 100
Fair
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability0=
Solvency77▲+20
Growth32=
Track record100
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €100k at 30 days only on tighter terms
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity short (current ratio 0.58 against 0.32 in 2024; short-term debt: 37% and cash: 12.2% of total assets), and 47.9% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Sector 72
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
24 d early
2024
96 d late
2023
6 d late
2022
34 d early
2021
40 d early
2020
32 d early
2019
31 d late
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
24-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€1.77M▲ 98.3%
2024 · €891k
2018: €2.17M
2019: €1.01M
2020: €-396k
2021: €2.74M
2022: €1.22M
2023: €1.67M
2024: €891k
2018 → 2025
Total assets
€3.39M▲ 23.7%
2024 · €2.74M
2018: €2.96M
2019: €2.24M
2020: €3.31M
2021: €3.53M
2022: €2.65M
2023: €3.61M
2024: €2.74M
2018 → 2025
Net result
€-1.22M▲ 8.6%
2024 · €-1.34M
2018: €-1.15M
2019: €-1.18M
2020: €-1.33M
2021: €-1.33M
2022: €-1.43M
2023: €-1.36M
2024: €-1.34M
2018 → 2025
Working capital
€-532k▲ 39.8%
2024 · €-884k
2018: €1.33M
2019: €40k
2020: €-1.73M
2021: €1.19M
2022: €400k
2023: €681k
2024: €-884k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€2.74M-€1.22M▼ 55.4%€1.67M▲ 36.5%€891k▼ 46.6%€1.77M▲ 98.3%
Operating result€-1.41M-€-1.51M▼ 7.2%€-1.39M▲ 8.0%€-1.44M▼ 4.0%€-1.44M▲ 0.5%
Net result€-1.33M-€-1.43M▼ 7.8%€-1.36M▲ 4.9%€-1.34M▲ 1.9%€-1.22M▲ 8.6%
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €1.44M in 2025 against €1.44M in 2024; the loss shrinks.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €3.39M
Fixed assets
€2.67M ▲ 14.8%
Current assets
€723k ▲ 72.8%
Equity and liabilities €3.39M
Equity
€1.77M ▲ 98.3%
Debt
€1.63M ▼ 12.2%
Debt's share of the balance-sheet total falls from 67.5% to 47.9%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€-582k▲
2024 · €-696k
Cash flow
€-365k▲
2024 · €-587k
Current ratio
0.58▲
2024 · 0.32
Quick ratio
0.56▲
2024 · 0.32
Debt to equity
0.92▼
2024 · 2.08
ROE
-69.2%▲
2024 · -150.0%
ROA
-36.0%▲
2024 · -48.7%
Interest coverage
-6.78▲
2024 · -21.98
Debt ≤ 1 year
€1.26M▼
2024 · €1.30M
Debt > 1 year
€346k▼
2024 · €550k
Staff costs
€524k▲
2024 · €462k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 60 lines
Balance sheet
Code20242025
Assets
Total assets20/58€2.74M€3.39M▲
Fixed assets21/28€2.33M€2.67M▲
Intangible fixed assets21€2.16M€2.55M▲
Tangible fixed assets22/27€137k€73k▼
Plant, machinery and equipment23€110k€60k▼
Furniture and vehicles24€3k€5k▲
Leasing and similar rights25€17k€3k▼
Other tangible fixed assets26€7k€6k▼
Financial fixed assets28€25k€45k▲
Current assets29/58€418k€723k▲
Stocks and contracts in progress3€0€23k▲
Stocks30/36€0€23k▲
Amounts receivable within one year40/41€188k€279k▲
Trade receivables40€146k€87k▼
Other amounts receivable41€43k€192k▲
Current investments50/53€0-
Cash at bank and in hand54/58€221k€413k▲
Deferred charges and accrued income490/1€9k€8k▼
Equity and liabilities
Total equity and liabilities10/49€2.74M€3.39M▲
Equity10/15€891k€1.77M▲
Contributions10/11€2.79M€4.29M▲
Capital10€167k€1.67M▲
Issued capital100€167k€1.67M▲
Outside capital11€2.62M€2.62M=
Share premium1100/10€2.62M€2.62M=
Profit (loss) carried forward14€-2.67M€-3.89M▼
Investment grants15€769k€1.37M▲
Amounts payable17/49€1.85M€1.63M▼
Amounts payable after more than one year17€550k€346k▼
Financial debts170/4€550k€346k▼
Amounts payable within one year42/48€1.30M€1.26M▼
Current portion of amounts payable after more than one year42€254k€241k▼
Financial debts43-€670k
Credit institutions430/8-€670k
Trade debts44€391k€194k▼
Suppliers440/4€391k€194k▼
Taxes, remuneration and social security45€53k€59k▲
Remuneration and social security454/9€53k€59k▲
Other amounts payable47/48€606k€92k▼
Accrued charges and deferred income492/3€106€25k▲
Income statement
Code20242025
Non-recurring operating income76A-€2k
Remuneration, social security and pensions62€462k€524k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€749k€856k▲
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€172k€-172k▼
Other operating charges640/8€28k€26k▼
Non-recurring operating charges66A€399€795▲
Gross operating margin9900€-33k€-203k▼
Operating profit (loss)9901€-1.44M€-1.44M▲
Financial income75/76B€140k€302k▲
Recurring financial income75€140k€302k▲
Financial charges65/66B€32k€86k▲
Recurring financial charges65€32k€86k▲
Profit (loss) for the period before taxes9903€-1.34M€-1.22M▲
Profit (loss) for the period9904€-1.34M€-1.22M▲
Profit (loss) for the period to be appropriated9905€-1.34M€-1.22M▲
Appropriation of the result
Profit (loss) to be appropriated9906€-2.67M€-3.89M▼
Profit (loss) brought forward from the previous period14P€-1.33M€-2.67M▼
Transfer from equity791/2€0-
Transfer to equity691/2€0-
To contributions691€0-
The notes to these accounts (23 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
07-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
23-02
State Gazette act
Capital & shares · Statutes amendmentCapital increase · Bank account · Capital7 facts ▸
State Gazette act
Capital & shares · Statutes amendment
Capital increase · Bank account · Capital7 facts ▸
- Board meeting, 11-02-2026
- Capital increase, €500.035,4
- Bank account, BE89 3632 6945 1185
- Capital, €2.149.578,04
- Statutes amendment
- Agreement, Subscription And Share Purchase Agreement du 26 septembre 2025
- Share class structure
2025
31-12
Financial
Equity above €1MEq €1.77M ▲98.3%
Equity rises from €891k to €1.77M.
30-12
State Gazette act
Appointment: Émilie Dory (directrice générale et déléguée à la gestion journalière)Resignation: Galibier Life Sciences LTD (daily management delegate)3 facts ▸
State Gazette act
Appointment: Émilie Dory (directrice générale et déléguée à la gestion journalière)
Resignation: Galibier Life Sciences LTD (daily management delegate)3 facts ▸
- Board meeting, 11-02-2025
- Director appointment, Émilie Dory (directrice générale et déléguée à la gestion journalière)
- Director resignation, Galibier Life Sciences LTD (daily management delegate)
04-11
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 96 days late
27-10
State Gazette act
Resignation: GALIBIER LIFE SCIENCES LTD (managing director)Appointments: ER ORAL SURGERY, HALDYR and 4 others · Permanent representative: DELFORGE Julie · Capital increase21 facts ▸
State Gazette act
Resignation: GALIBIER LIFE SCIENCES LTD (managing director)
Appointments: ER ORAL SURGERY, HALDYR and 4 others · Permanent representative: DELFORGE Julie · Capital increase21 facts ▸
- General meeting, 01-10-2025
- Capital increase, €1.500.106,2
- Capital, €1.649.542,64
- Share issue, Droits de Souscription, 4724
- Share cancellation, 853, 299 attribués et 554 non attribués
- Director resignation, GALIBIER LIFE SCIENCES LTD (managing director)
- Director appointment, ER ORAL SURGERY (director)
- Director appointment, HALDYR (director)
- Director appointment, OUSIA OPERATIONS (director)
- Director appointment, THOMAS LIENARD (director)
- Director appointment, WEBER William (director)
- Mandate compensation, ER ORAL SURGERY
- +9 further facts in this act
2024
06-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 6 days late
2023
01-08
State Gazette act
Capital & shares · Statutes amendmentCapital increase · Capital · Statutes amendment7 facts ▸
State Gazette act
Capital & shares · Statutes amendment
Capital increase · Capital · Statutes amendment7 facts ▸
- General meeting, 04-07-2023
- Capital increase, €17.321,16
- Capital, €166.757,6
- Statutes amendment
- Power of attorney, Conseil d'Administration
- Authorised capital, C2, 145
- Share class creation, mêmes droits et avantages que les actions existantes des autres classes, à l'exception d'un Droit de Liquidation Préférentielle
27-06
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
20-02
State Gazette act
Capital & shares · Statutes amendmentReserve release · Capital increase · Capital decrease8 facts ▸
State Gazette act
Capital & shares · Statutes amendment
Reserve release · Capital increase · Capital decrease8 facts ▸
- General meeting, 26-01-2023
- Reserve release, Suppression du caractère indisponible des primes d'émission
- Capital increase, €3.500.000
- Capital decrease, €3.500.000
- Capital, €149.436,44
- Statutes amendment
- Power of attorney, Conseil d'administration
- Share classes, Toutes les actions bénéficient de droits identiques indépendamment de la catégorie à laquelle elles appartiennent, sauf s'il en est disposé autrement dans les p…
2022
31-12
Financial
Weakest financial yearnet €-1.43M
Net result drops to €-1.43M, the lowest in the series; recovery starts the following year.
01-09
State Gazette act
Resignation: NOSHAQ PARTNERS SCRL (director)Appointment: OUSIA OPERATIONS SRL (director)3 facts ▸
State Gazette act
Resignation: NOSHAQ PARTNERS SCRL (director)
Appointment: OUSIA OPERATIONS SRL (director)3 facts ▸
- General meeting, 03-06-2022
- Director resignation, NOSHAQ PARTNERS SCRL (director)
- Director appointment, OUSIA OPERATIONS SRL (director)
Show earlier events
21-06
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
31-12
Financial
Liquidity times 12current ratio 4.80
Current ratio from 0.40 to 4.80; short-term debt falls from €2.89M to €313k.
31-12
Financial
Equity above €2MEq €2.74M
Equity rises from €-396k to €2.74M.
26-11
State Gazette act
Resignations: France Lambert, Geoffrey Lecloux and 2 othersReappointments: SRL HALDYR, SRL ER ORAL SURGERY and 3 others · Permanent representatives: Simon Alexandre, Eric Rompen and 4 others · Appointment: SA INNODE (director)28 facts ▸
State Gazette act
Resignations: France Lambert, Geoffrey Lecloux and 2 others
Reappointments: SRL HALDYR, SRL ER ORAL SURGERY and 3 others · Permanent representatives: Simon Alexandre, Eric Rompen and 4 others · Appointment: SA INNODE (director)28 facts ▸
- General meeting, 29-10-2021
- Capital increase, €19.247,16
- Bank account, ING, BE54 3632 1517 1197
- Capital, €149.436,44
- Statutes amendment
- Director resignation, France Lambert (director)
- Director resignation, Geoffrey Lecloux (director)
- Director resignation, SA SPARAXIS (director)
- Director reappointment, SRL HALDYR (director)
- Permanent representative, Simon Alexandre
- Director reappointment, SRL ER ORAL SURGERY (director)
- Permanent representative, Eric Rompen
- +16 further facts in this act
02-07
State Gazette act
Appointment: Galibier Life Sciences Ltd (day-to-day manager)Permanent representatives: Daniel BEE and Caroline THIELEN · Resignation: Géry LEFEBVRE (permanent representative)5 facts ▸
State Gazette act
Appointment: Galibier Life Sciences Ltd (day-to-day manager)
Permanent representatives: Daniel BEE and Caroline THIELEN · Resignation: Géry LEFEBVRE (permanent representative)5 facts ▸
- General meeting, 28-05-2021
- Director appointment, Galibier Life Sciences Ltd (day-to-day manager)
- Permanent representative, Daniel BEE
- Permanent representative, Caroline THIELEN
- Director resignation, Géry LEFEBVRE (permanent representative)
29-06
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
28-06
State Gazette act
Capital & shares · Statutes amendmentStatutes amendment · Capital · Capital contribution5 facts ▸
State Gazette act
Capital & shares · Statutes amendment
Statutes amendment · Capital · Capital contribution5 facts ▸
- General meeting, 31/05/2021
- Statutes amendment
- Capital, €104.059,88
- Capital contribution
- Share issue, Apport de créances en capital par Noshaq VENTURE, EPIMEDE, The Faktory, S.R.I.W et Financière Spin-off Luxembourgeoise SA
89.1% of this act was read; anything after the cut is not in this list.Read the act at the Belgisch Staatsblad ↗
2020
08-12
State Gazette act
Appointment: SRL Thomas Liénard (independent director)Permanent representative: Thomas Liénard3 facts ▸
State Gazette act
Appointment: SRL Thomas Liénard (independent director)
Permanent representative: Thomas Liénard3 facts ▸
- General meeting, 21-09-2020
- Director appointment, SRL Thomas Liénard (independent director)
- Permanent representative, Thomas Liénard
31-08
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 31 days late
25-02
State Gazette act
Permanent representative: Marc FOIDART1 fact ▸
State Gazette act
Permanent representative: Marc FOIDART
1 fact ▸
- Permanent representative, Marc FOIDART
2019
30-08
State Gazette act
Permanent representative: Eric Rompen2 facts ▸
State Gazette act
Permanent representative: Eric Rompen
2 facts ▸
- General meeting, 27-06-2019
- Permanent representative, Eric Rompen
29-08
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 29 days late
03-05
State Gazette act
Resignation: Eric Rompen Implantologie (administrateur, administrateur délégué et président du conseil d'administration)Appointment: ER Oral Surgery (administrateur, administrateur délégué et président du conseil)3 facts ▸
State Gazette act
Resignation: Eric Rompen Implantologie (administrateur, administrateur délégué et président du conseil d'administration)
Appointment: ER Oral Surgery (administrateur, administrateur délégué et président du conseil)3 facts ▸
- Board meeting, 14-12-2018
- Director resignation, Eric Rompen Implantologie (administrateur, administrateur délégué et président du conseil d'administration)
- Director appointment, ER Oral Surgery (administrateur, administrateur délégué et président du conseil)
2018
30-08
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema · 30 days late
01-08
State Gazette act
Resignation: WISHBONE (director)Appointments: SPRL Haldyr, SPRL ERIC ROMPEN IMPLANTOLOGIE and 5 others · Permanent representatives: Simon ALEXANDRE, Eric ROMPEN and 2 others · Share cancellation34 facts ▸
State Gazette act
Resignation: WISHBONE (director)
Appointments: SPRL Haldyr, SPRL ERIC ROMPEN IMPLANTOLOGIE and 5 others · Permanent representatives: Simon ALEXANDRE, Eric ROMPEN and 2 others · Share cancellation34 facts ▸
- General meeting, 09-07-2018
- Share cancellation, parts bénéficiaires, 4250
- Capital increase, €11.767,86
- Capital increase, €26.842,02
- Capital, €104.059,88
- Share issue, 853, 853
- Bank account, SA ING Belgium, BE93 3631 7436 0267
- Statutes amendment
- Director resignation, WISHBONE
- Director appointment, SPRL Haldyr (director)
- Permanent representative, Simon ALEXANDRE
- Director appointment, SPRL ERIC ROMPEN IMPLANTOLOGIE (director)
- +22 further facts in this act
2017
29-08
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema · 29 days late
12-07
State Gazette act
Reappointments: Eric ROMPEN, France LAMBERT and 3 others6 facts ▸
State Gazette act
Reappointments: Eric ROMPEN, France LAMBERT and 3 others
6 facts ▸
- General meeting, 19-05-2016
- Director reappointment, Eric ROMPEN (director)
- Director reappointment, France LAMBERT (director)
- Director reappointment, Geoffrey LECLOUX (director)
- Director reappointment, Pierre L'HOEST (director)
- Director reappointment, Simon ALEXANDRE (director)
2016
19-02
State Gazette act
Registered officeRegistered-office move2 facts ▸
State Gazette act
Registered office
Registered-office move2 facts ▸
- Board meeting
- Registered-office move, N°1, Boîte 3, rue de l'Expansion, à 4400 Flemalle
2015
09-06
State Gazette act
Capital & sharesCapital increase · Bank account · Reserve release6 facts ▸
State Gazette act
Capital & shares
Capital increase · Bank account · Reserve release6 facts ▸
- General meeting, 21-05-2015
- Capital increase, €2.200
- Bank account, be 363 148172893
- Reserve release, prime d'émission portée à un compte de réserve indisponible
- Capital, €65.450
- Statutes amendment
2013
24-12
State Gazette act
IncorporationAppointments: Pierre L'HOEST, Simon Alexandre and 3 others · Founding capital · Bank account12 facts ▸
State Gazette act
Incorporation
Appointments: Pierre L'HOEST, Simon Alexandre and 3 others · Founding capital · Bank account12 facts ▸
- Incorporation, 19-12-2013
- Founding capital, €63.250
- Bank account, ING
- Founder, Eric Henri Rompen
- Director appointment, Pierre L'HOEST (director)
- Director appointment, Simon Alexandre (director)
- Director appointment, Eric Henri Rompen (director)
- Director appointment, France Emmanuelle Lambert (director)
- Director appointment, Geoffrey Hélène Lecloux (director)
- Mandate compensation, Wishbone
- First general meeting, troisième jeudi du mois de mai 2015
- Beneficial shares, 5100, 850
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
19 directors, last change in 2025
HALDYR
CurrentDirector · since 01-10-2025 · Legal entity
OUSIA OPERATIONS
CurrentDirector · since 01-10-2025 · Legal entity
THOMAS LIENARD
CurrentDirector · since 01-10-2025 · Legal entity
WEBER William
CurrentDirector · since 01-10-2025
Émilie Dory
CurrentDirectrice générale et déléguée à la gestion journalière · since 06-11-2023
OUSIA OPERATIONS
CurrentDirector · since 03-06-2022 · Private limited company
13 other directors
INNODE
CurrentDirector · since 29-10-2021 · Public limited company · perm. rep.: François Blondel
THOMAS LIENARD
CurrentIndependent director · since 21-09-2020 · Private limited company · perm. rep.: Thomas Liénard
ER Oral Surgery
CurrentDirector · since 01-01-2019 · Legal entity
HALDYR
CurrentDirector · since 09-07-2018 · Private limited company · perm. rep.: Simon ALEXANDRE
NOSHAQ PARTNERS
CurrentDirector · since 09-07-2018 · Private limited company · perm. rep.: Joanna TYREKIDIS
ER Oral Surgery
CurrentDirector · Private limited company · perm. rep.: Eric Rompen
SPARAXIS
Not recently confirmedDirector · since 09-07-2018 · Public limited company · perm. rep.: Géry LEFEBVRE
Eric Rompen
Not recently confirmedDirector · since 19-05-2016
Pierre L'HOEST
Not recently confirmedDirector · since 19-12-2013
Simon Alexandre
Not recently confirmedDirector · since 19-12-2013
Eric Henri Rompen
Not recently confirmedDirector · since 19-12-2013
France Emmanuelle Lambert
Not recently confirmedDirector · since 19-12-2013
Geoffrey Hélène Lecloux
Not recently confirmedDirector · since 19-12-2013
01-10-2025
HALDYR: Appointed as Director
01-10-2025
OUSIA OPERATIONS: Appointed as Director
01-10-2025
THOMAS LIENARD: Appointed as Director
01-10-2025
WEBER William: Appointed as Director
01-10-2025
ER Oral Surgery: Appointed as Director
Not every act has been read: a resignation may be missing here
1 act was read only in part. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Flémalle · 1 establishment unit since 2015
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue de l'Expansion 14400 Flémalle1 establishment unit
Rue de l'Expansion 1, 4400 Flémalle
since 20152.238.442.373
Statutory auditor
1 auditor| Deloitte Bedrijfsrevisoren/Réviseurs d’EntreprisesCurrent Statutory auditor · represented by DELFORGE Julie | 01-01-2024 → present |
Show 1 earlier auditors
| Deloitte Réviseurs d'Entreprises Auditor · represented by Julie Delforge succeeded by Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises in 2024 | 09-07-2018 → 01-01-2024 |
Articles of association
Purpose
La société a pour objet, tant en Belgique qu'à l'étranger, seule ou en association avec des tiers, le développement, la fabrication, la commercialisation et l'exploitation, sous…
Full purpose
La société a pour objet, tant en Belgique qu'à l'étranger, seule ou en association avec des tiers, le développement, la fabrication, la commercialisation et l'exploitation, sous quelque forme que ce soit, y compris par l'octroi à des tiers de brevets ou de licences, de matériaux de régénération et de cicatrisation tissulaire ainsi que de tout produit similaire, comparable ou complémentaire.
Structure & network
Connections & network
34 connected companiesLinked via shared directors
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Show 30 more companies with a shared director
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Capital and shareholders
Shareholders according to the acts
After the capital increase
act of 09-06-2015 ↗
- Belinvest 64 shares · 32,000 EUR
- Eric Rompen 68 shares · 34,000 EUR
- France Lambert 34 shares · 17,000 EUR
- Geoffrey LECLOUX 34 shares · 17,000 EUR
At incorporation
act of 24-12-2013 ↗
- Eric Henri Rompen founder
The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.
Capital over the years
- 23-02-2026 Capital increase of 500,035.40 EUR · to 2,149,578.04 EUR · 2,362 new shares · in cash
- 27-10-2025 Capital increase of 1,500,106.20 EUR · to 1,649,542.64 EUR · 7,086 new shares
- 01-08-2023 Capital increase of 17,321.16 EUR · to 166,757.60 EUR · 2,698 new shares
- 20-02-2023 Capital increase of 3,500,000 EUR · to 3,649,436.44 EUR · no new shares · from reserves
- 20-02-2023 Capital reduction of 3,500,000 EUR · to 149,436.44 EUR · to absorb losses
- 26-11-2021 Capital increase of 19,247.16 EUR · to 149,436.44 EUR · 2,998 new shares
- 28-06-2021 Capital stated in the act · 104,059.88 EUR · 16,214 shares
- 01-08-2018 Capital increase of 11,767.86 EUR · to 77,217.86 EUR · 1,833 new shares · in kind
Show 3 older capital entries
- 01-08-2018 Capital increase of 26,842.02 EUR · to 104,059.88 EUR · 4,181 new shares · in cash
- 09-06-2015 Capital increase of 2,200 EUR · to 65,450 EUR · 200 new shares
- 24-12-2013 Incorporation · 63,250 EUR · 5,750 shares
Similar companies · same sector, comparable size
CM4Cure
BE 0765.658.810
Liège · Eq €1.77M
DR. JOHAN VANDEN BROUCKE
BE 0479.040.735
Ieper · Eq €1.78M
THERAtRAME
BE 0786.448.581
Liège · Eq €1.75M
DOKTER FRANKIE NOBELS
BE 0480.141.288
Dendermonde · Eq €1.73M
OP2LYSIS DEVELOPMENT
BE 0769.816.843
Liège · Eq €1.82M
Of 761 companies in sector 72101 we hold annual accounts for 481. 268 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPublic limited company
Founded20-12-2013
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
Sources
Crossroads Bank for EnterprisesNational Bank · 12 filings
Scores and ratios are computed by Checked and are not a credit decision.